Tags

Type your tag names separated by a space and hit enter

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.
Cells. 2020 Jun 03; 9(6)C

Abstract

Alemtuzumab is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. It is currently used as an immune reconstitution therapy in patients with relapsing-remitting multiple sclerosis. Alemtuzumab treatment is an intermittent infusion that induces long-term remission of Multiple Sclerosis also in the treatment-free period. After the robust T and B cell depletion induced by alemtuzumab, the immune system undergoes radical changes during its reconstitution. In this review, we will discuss the current knowledge on the reconstitution of the lymphocyte repertoire after alemtuzumab treatment and how it could affect the development of side effects, which led to its temporary suspension by the European Medical Agency.

Authors+Show Affiliations

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano (TO), Italy.Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano (TO), Italy.Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano (TO), Italy.Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano (TO), Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32503344

Citation

Rolla, Simona, et al. "The Meaning of Immune Reconstitution After Alemtuzumab Therapy in Multiple Sclerosis." Cells, vol. 9, no. 6, 2020.
Rolla S, Maglione A, De Mercanti SF, et al. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. Cells. 2020;9(6).
Rolla, S., Maglione, A., De Mercanti, S. F., & Clerico, M. (2020). The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. Cells, 9(6). https://doi.org/10.3390/cells9061396
Rolla S, et al. The Meaning of Immune Reconstitution After Alemtuzumab Therapy in Multiple Sclerosis. Cells. 2020 Jun 3;9(6) PubMed PMID: 32503344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. AU - Rolla,Simona, AU - Maglione,Alessandro, AU - De Mercanti,Stefania Federica, AU - Clerico,Marinella, Y1 - 2020/06/03/ PY - 2020/05/04/received PY - 2020/06/02/revised PY - 2020/06/02/accepted PY - 2020/6/7/entrez PY - 2020/6/7/pubmed PY - 2020/6/7/medline KW - Alemtuzumab KW - immune reconstitution KW - mode of action KW - multiple sclerosis JF - Cells JO - Cells VL - 9 IS - 6 N2 - Alemtuzumab is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. It is currently used as an immune reconstitution therapy in patients with relapsing-remitting multiple sclerosis. Alemtuzumab treatment is an intermittent infusion that induces long-term remission of Multiple Sclerosis also in the treatment-free period. After the robust T and B cell depletion induced by alemtuzumab, the immune system undergoes radical changes during its reconstitution. In this review, we will discuss the current knowledge on the reconstitution of the lymphocyte repertoire after alemtuzumab treatment and how it could affect the development of side effects, which led to its temporary suspension by the European Medical Agency. SN - 2073-4409 UR - https://www.unboundmedicine.com/medline/citation/32503344/The_Meaning_of_Immune_Reconstitution_after_Alemtuzumab_Therapy_in_Multiple_Sclerosis L2 - https://www.mdpi.com/resolver?pii=cells9061396 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.